Dengue vaccine study

By Dylan Bushell-Embling
Tuesday, 02 September, 2008

Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.

WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.

The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.

Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

AMS announces 2026 Beamex User Group meeting

Businesses use AI to manage sustainability reporting

Victorian wind farm project to power 1.2 million homes

SA retirement village reduces energy costs using solar system

Battery-free sensors close to reality

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Additional $22.9m in research grants for nation's biggest killer

The important role of software engineering in industry

Biome Australia brings probiotic manufacturing to Australia

AMS announces 2026 Beamex User Group meeting

A high-speed, real-time optical data connection for industrial applications

Redesigning for decarbonisation: the shift towards electrified hydraulic power